Lucid Diagnostics Inc
LUCD
Company Profile
Business description
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Contact
360 Madison Avenue
25th Floor
New YorkNY10017
USAT: +1 917 813-1828
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
82
Stocks News & Analysis
stocks
Weight loss drugs not an existential threat to undervalued ASX share
A durable growth story despite GLP-1 headwinds.
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
We see regulatory risk from both the US and Chinese governments.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.60 | 20.80 | 0.23% |
| CAC 40 | 7,847.32 | 64.50 | 0.83% |
| DAX 40 | 25,410.84 | 229.19 | 0.91% |
| Dow JONES (US) | 52,361.58 | 146.42 | 0.28% |
| FTSE 100 | 10,767.33 | 76.97 | 0.72% |
| HKSE | 23,211.81 | 118.44 | 0.51% |
| NASDAQ | 26,169.38 | 214.04 | 0.82% |
| Nikkei 225 | 62,189.65 | 503.51 | -0.80% |
| NZX 50 Index | 13,701.88 | 32.05 | -0.23% |
| S&P 500 | 7,676.77 | 53.09 | 0.70% |
| S&P/ASX 200 | 8,809.90 | 14.70 | 0.17% |
| SSE Composite Index | 3,697.52 | 7.04 | 0.19% |